Weight loss drugs took health care by storm in 2023 🩺 Ro CEO Z Reitano walks us through the increased demand he's seeing for obesity treatments and how his platform uses telehealth to oversee prescriptions for eligible patients.

Our CEO, Z Reitano joined Katie Greifeld and David Westin on Bloomberg TV to discuss the unprecedented demand for anti-obesity medications and why so many patients are choosing to get care through Ro. youtube.com/watch?v=dzerYS…

Our CEO, Z Reitano, emphasized the profound impact that anti-obesity medications could have on the healthcare system and beyond. Tune into his conversation w/ Bob Safian on the Masters of Scale podcast.

Lived experiences always foster the most needed innovation. When 776 portco Ro Founder + CEO Z Reitano witnessed the impact GLP1s had on his dad’s health, he knew Ro could scale access to the kind of obesity care his dad experienced. The Ro team got to work 😤 🔥

What motivates people to lose weight? This is an important topic. At @Ro, we’re constantly speaking to our patients to understand their goals and their reasons for joining our Body Program. Check out some of that data and what it says about men and women’s motivations for seeking

Ro's direct-to-patient care makes it easier for patients to get the effective care they need. Now, we're showing off ro.OS (the Ro Operating System), our tech platform that makes this DTP care possible and helps more patients to achieve their goals. ro.co/os/

At the #FTPharma Summit, our CEO Z Reitano shared how direct-to-patient channels like Ro helped usher in a new way of thinking about patient-centric care that can better meet patients' rising expectations – making it easier to get the effective care they need.

Our CEO, Z Reitano joined Bloomberg TV today to discuss how Ro helps each patient access the best possible treatment for their goals, even during the GLP-1 shortage. bloomberg.com/news/videos/20…

"We are dramatically underestimating the demand," Ro CEO Zach Reitano says on GLP-1 drugs. "I think we're going to see that demand/supply mismatch for years."

GLP-1 drugs are in short supply, but a new supply tracker could help patients find what they need @Ro CEO and Co-Founder Z Reitano breaks down his company's newest tracker and how producers like $LLY and $NVO are handling supply and distribution obstacles:

Everyone deserves access to the treatment they need. If you or someone you know is at risk of losing coverage for your GLP-1 treatment in Michigan, Ro wants to help. Learn more below.

GLP-1s represent a giant leap forward in treating obesity, but every day patients still face serious challenges related to these medications. What if it only gets better from here though? Ro’s CEO, Z Reitano offers a look ahead. ro.co/perspectives/w…

Do people on GLP-1s lose more muscle than those who lose weight through other means? Our team and Ro’s advisor, David Allison, looked at the evidence related to GLP-1s’ effect on muscle mass, body composition, and physical function. ro.co/perspectives/g…

Digital health company Ro launches GLP-1 insurance-coverage checker to help patients navigate costs cnbc.com/2024/08/13/ro-…

Introducing the GLP-1 Insurance Coverage Checker – a free tool that empowers anyone to easily check if their insurance covers GLP-1s medications and understand their potential OOP costs at the very beginning of their journey. ro.co/weight-loss/gl…

Checking GLP-1 drug insurance coverage just got a little easier, thanks to a new tool from Ro. CEO Z Reitano explains how it works. He also gives his read on the blockbuster obesity drug market.

At Ro, we are rooting for the GLP-1 shortages to end ASAP. Since introducing our GLP-1 Supply Tracker three months ago though, we've received over 60k drug shortage reports. Dive into our latest blog to learn what this data reveals about the shortages: ro.co/news/glp1-supp…

Thanks for standing tall, shannon sharpe. You're not the only one getting it in - we created Ro Sparks to help millions of guys do the act. We got you 💪